Effectiveness of sparfloxacin for Chlamydia pneumoniae infection in patients with bronchial asthma

Takahiko Horiguchi, Soichi Tachikawa, Junichi Kasahara

研究成果: Article査読

抄録

In order to evaluate the effectiveness of sparfloxacin (SPFX), a synthetic new quinolone antibacterial agent 26 patients with bronchial asthma, in whom Chlamydia (C.) pneumoniae IgG and IgA antibody titers (ID) were elevated more than 1.01 were studied. They were divided at random into two groups: SPFX administration group (14 patients) and non-administration group (12 patients). In SPFX administration group, 200mg/day of this drug was administered for 3 weeks. In the SPFX administration group, a significant improvement in serum CRP, and significant decreases in peripheral eosinophil count, serum ECP, and sputum ECP were observed. Furthermore, there were also noted significant decreases in frequency of asthmatic attacks in frecuency of inhalation of β2 stimulant, and a significant increse in PEE in the morning. Thus, it was suggested that administration of SPFX was effective for patients with bronchial asthma accompanying persistent C. pneumoniae infection.

本文言語English
ページ(範囲)453-459
ページ数7
ジャーナルJapanese Journal of Chest Diseases
61
5
出版ステータスPublished - 18-06-2002

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

フィンガープリント 「Effectiveness of sparfloxacin for Chlamydia pneumoniae infection in patients with bronchial asthma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル